|
|
|
실제 임상에서 특발성 과민성 방광 환자들에서 onabotulinumtoxinA 방광내 주사의 효능과 안정성 |
| 성균관대학교 의과대학, 삼성서울병원, 비뇨의학과교실 |
| 변혜진, 최중원, 이규성 |
Introduction: The aim of this study is to determine the safety and efficacy of onabotulinumtoxinA for patients with overactive bladder (OAB) in real clinical practice.
Methods: This is a retrospective study conducted at single center from December 2012 to January 2019. Patients received onabotulinumtoxinA 100U due to idiopathic OAB who had an inadequate response to or were intolerant of anticholinergics were analyzed. Efficacy was assessed using the Overactive Bladder Symptom Score (OABSS) and 3-day voiding diary parameters that was completed before and 1-4 months after treatment. And we also evaluated the ratio of re-treatment and time to interval between treatment.
Results: Overall, 226 patients were included. The mean age was 62.1 years, and the ratio of female patients was 63.4 %. After treatment, total OABSS, OABSS urgency sub-score (Q3) were decreased from 10.2 to 7.5, from 4.0 to 2.9 (p<0.001), respectively. Mean number of micturition was decreased from 13.5 to 10.8 times (p<0.001). Maximum flow rate (15.0 to 13.4 ml/s, p=0.054) and voided volume (147 to 138 cc, p=0.317) were not significantly changed. However, the post-residual urine was increased from 31 to 103 ml (p<0.001). The most common adverse event was acute urinary retention 5.3% (12/226). 41.5% (94/226) of patients received 2 or more onabotulinumtoxinA administration at median 12 months, and the mean number of treatment was 2.76 times.
Conclusions: OnabotulinumtoxinA 100U significantly improved OAB symptoms and was well tolerated in patients who were inadequately treated with anticholinergics. |
  |
|
keywords : overactive bladder, onabotulinumtoxinA |
|
